Regeneron to highlight pioneering pipeline progress across multiple modalities spanning 10 types of blood cancers and disorders at ash

Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria

REGN Ratings Summary

REGN Quant Ranking